Dev Prasad
Stock Analyst at Lucid Capital
(4.40)
# 1,282
Out of 5,152 analysts
24
Total ratings
38.1%
Success rate
41.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dev Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CUE Cue Biopharma | Reiterated: Buy | n/a | $4.50 | - | 2 | Nov 18, 2026 | |
| FTH Faeth Therapeutics | Reiterated: Buy | $59 | $8.69 | +578.94% | 2 | Nov 9, 2026 | |
| ABOS Acumen Pharmaceuticals | Downgraded: Hold | $6 → $1 | $0.1933 | +417.33% | 2 | Nov 2, 2026 | |
| TTRX Turn Therapeutics | Initiated Coverage: Buy | $24 | $8.64 | +177.78% | 1 | Sep 24, 2026 | |
| GNLX Genelux | Initiated Coverage: Buy | $18 | $2.28 | +689.47% | 1 | Sep 16, 2026 | |
| ANL Adlai Nortye Group | Initiated Coverage: Buy | $49 | $9.06 | +440.84% | 1 | Sep 8, 2026 | |
| ELOX Eloxx Pharmaceuticals | Initiated Coverage: Buy | $38 | $10.65 | +256.81% | 1 | Aug 20, 2026 | |
| PLYX Polaryx Therapeutics | Initiated Coverage: Buy | $7 | $1.51 | +363.58% | 1 | Jul 27, 2026 | |
| QNRX Quoin Pharmaceuticals | Initiated Coverage: Buy | $30 | $3.36 | +793.10% | 1 | May 4, 2026 | |
| PVLA Palvella Therapeutics | Reiterated: Buy | $49 → $212 | $145.77 | +45.43% | 2 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $1.09 | n/a | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $19 | $2.89 | n/a | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $4.00 | $0.22 | n/a | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $1 | $3.69 | n/a | 1 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $4.08 | n/a | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 | $2.18 | n/a | 1 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $36 | $1.25 | n/a | 1 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $24 | $6.75 | n/a | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $1.17 | n/a | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 | $0.801 | n/a | 1 | Dec 17, 2024 |
Cue Biopharma
Nov 18, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.50
Upside: -
Faeth Therapeutics
Nov 9, 2026
Reiterated: Buy
Price Target: $59
Current: $8.69
Upside: +578.94%
Acumen Pharmaceuticals
Nov 2, 2026
Downgraded: Hold
Price Target: $6 → $1
Current: $0.1933
Upside: +417.33%
Turn Therapeutics
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $24
Current: $8.64
Upside: +177.78%
Genelux
Sep 16, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $2.28
Upside: +689.47%
Adlai Nortye Group
Sep 8, 2026
Initiated Coverage: Buy
Price Target: $49
Current: $9.06
Upside: +440.84%
Eloxx Pharmaceuticals
Aug 20, 2026
Initiated Coverage: Buy
Price Target: $38
Current: $10.65
Upside: +256.81%
Polaryx Therapeutics
Jul 27, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $1.51
Upside: +363.58%
Quoin Pharmaceuticals
May 4, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $3.36
Upside: +793.10%
Palvella Therapeutics
Dec 15, 2025
Reiterated: Buy
Price Target: $49 → $212
Current: $145.77
Upside: +45.43%
Nov 10, 2025
Reiterated: Buy
Price Target: $24
Current: $1.09
Upside: n/a
Nov 5, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $2.89
Upside: n/a
Oct 14, 2025
Initiated Coverage: Buy
Price Target: $4.00
Current: $0.22
Upside: n/a
Sep 15, 2025
Downgraded: Hold
Price Target: $1
Current: $3.69
Upside: n/a
Jun 17, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $4.08
Upside: n/a
May 23, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $2.18
Upside: n/a
May 1, 2025
Initiated Coverage: Buy
Price Target: $36
Current: $1.25
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $24
Current: $6.75
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $13
Current: $1.17
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $6
Current: $0.801
Upside: n/a